Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xe129 MRI to Assess Advair Treatment for COPD
NCT02826343Phase 1Completed
- Sponsor
- University of Virginia
- Start
- May 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hyperpolarized xenon gas in chronic obstructive pulmonary disease (COPD), sponsored by University of Virginia. Primary endpoints: Improvement in pulmonary airflow physiology detected by Xenon129 MRI at 3 months and Improvement in pulmonary gas exchange physiology detected by Xenon129 MRI at 3 months. Started May 2016; status: completed.
02
Drugs
hyperpolarized xenon gas
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02826343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826343.